Canada

Canada Approves First Generic Ozempic in G7

Is generic semaglutide a treatment breakthrough or a public health disaster waiting to happen?

Published APR 29

Canada Approves First Generic Ozempic in G7

Story

Above: Dr. Reddy's Laboratories logo at the Bio Asia 2026 summit in Hyderabad, Telangana, India, on Feb. 18. Image credit: Jwala Kotesh/NurPhoto/Getty Images

The Facts

Health Canada approved the first generic version of Ozempic on Tuesday, making Canada the first G7 country to authorize a generic semaglutide injection. The drug was submitted by Dr. Reddy's Laboratories, based in Hyderabad, India.
Government of Canada
The approved generic semaglutide, sold in India under the brand name Obeda, covers 2 mg/pen and 4 mg/pen dosages and is indicated for once-weekly treatment of Type 2 diabetes in adults. Health Canada has confirmed the drug met safety, efficacy and quality standards.
Toronto Star
Moneycontrol
Global News
Novo Nordisk's Canadian patent on semaglutide expired Jan. 4, opening the market to generic competition. Between 2016 and 2025, Health Canada saw a 43% rise in generic drug submissions, contributing to a backlog of application reviews.
Toronto Sun
Bloomberg
Generic medications in Canada are typically 45-90% cheaper than brand-name versions. Under the pan-Canadian Pharmaceutical Alliance pricing structure, costs drop to about 35% of the brand-name price once three or more generics are available.
Ad Hoc News
Global News
The Canadian semaglutide market was valued at approximately $1.3 billion in 2026, with roughly 3.9 million Canadians living with diagnosed diabetes. In some global markets, generic competition is expected to reduce monthly treatment costs to as little as $14.
NDTV Profit
Bloomberg
Moneycontrol

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Narrative A

Generic semaglutide becoming legal in Canada is a massive win for public health — prices could drop by as much 65%, putting life-changing medication within reach for millions who couldn't previously afford it. Health Canada has several pending applications and Dr. Reddy's approved drug is only one among them. Every month of regulatory foot-dragging is a policy failure with a real price tag to Canadians waiting on more treatment options.

Dr. Peter A Singer on X

Saskatoon Star Phoenix

Narrative B

Flooding the market with cheap generic Ozempic without serious oversight is a recipe for a public health disaster. Half of users experience side effects, over 30% quit within a month, and the weight returns once the drug is stopped, meaning the supposed benefits are temporary at best. India's health authorities already sounded the alarm about unregulated access causing severe complications, and that warning deserves serious attention.

A Midwestern Doctor on X